GlassScriptPhysician profile
Steffani Citak
NPI 1023769452
$6,624.80
in general payments reported to CMS, 2019-2025
45 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,470 · 2023: $2,391 · 2024: $1,270 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,080 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,079.63 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $698.23 | 2022-2025 | |
| Abbvie INC. | $687.32 | 2022-2025 | |
| Novo Nordisk INC | $678.84 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $633.38 | 2022-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $383.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $306.14 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $261.87 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $229.43 | 2022-2024 | Xarelto |
| Corium, LLC | $226.03 | 2023-2024 | Azstarys |
| Esperion Therapeutics, INC. | $173.01 | 2022-2025 | Nexletol |
| Amgen INC. | $163.26 | 2022-2025 | Evenity, Otezla, Repatha |
| Ironshore Pharmaceuticals INC. | $156.12 | 2023-2024 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $154.46 | 2022-2025 | Airsupra, Breztri |
| Almatica Pharma LLC | $148.32 | 2022-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Abbott Laboratories | $147.82 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steffani Citak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.